Bio-Reference Laboratories (NAS: BRLI) reported earnings yesterday. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Jan. 31 (Q1), Bio-Reference Laboratories beat expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly, and GAAP earnings per share shrank.
Gross margins shrank, operating margins grew, and net margins contracted.
Bio-Reference Laboratories notched revenue of $149.9 million. The five analysts polled by S&P Capital IQ foresaw revenue of $143.1 million on the same basis. GAAP reported sales were 23% higher than the prior-year quarter's $121.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.26. The five earnings estimates compiled by S&P Capital IQ anticipated $0.21 per share. GAAP EPS of $0.26 for Q1 were 7.1% lower than the prior-year quarter's $0.28 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 47.5%, 130 basis points worse than the prior-year quarter. Operating margin was 8.9%, 170 basis points better than the prior-year quarter. Net margin was 4.9%, 170 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $160.3 million. On the bottom line, the average EPS estimate is $0.31.
Next year's average estimate for revenue is $654.1 million. The average EPS estimate is $1.40.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 298 members rating the stock outperform and 16 members rating it underperform. Among 96 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 95 give Bio-Reference Laboratories a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $21.50.
Over the decades, small-cap stocks, like Bio-Reference Laboratories have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
Add Bio-Reference Laboratories to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Bio-Reference Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.